A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors

Inclusion Criteria:

- ICGCT including pure germinoma and MMGCT.

- Patients with histologically proven germinoma and MMGCT, including endodermal sinus
tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell
tumor will be eligible for the study.

- Patients with mature/immature teratoma who have tumor marker elevations are eligible
on this study.

- Patient with ONLY mature and/or immature teratoma are ineligible in the absence of
the tumor marker elevations.

Exclusion Criteria:

- Patients with ICGCTs who are newly diagnosed are excluded from the study.

- Patients with the diagnosis of mature or immature teratoma in the absence of tumor
marker elevations are excluded from the study.

- Patients who are pregnant or breastfeeding are excluded from the study.

- Patients who have received previously a high dose chemotherapy regimen and autologous
transplant are excluded from this study.

- Patients who have received gemcitabine, oxaliplatin and/or paclitaxel are excluded
from this study.